Arcede Pharma is currently offering redemptions in TO1
| Published January 15, 2024

Arcede on the CEO change and preparations for Phase I

The Lund company Arcede Pharma is currently in the process of exercising its TO1 warrant, where it aims to raise approximately SEK 10 million. BioStock has invited CEO Mia Lundblad and Chairman of the Board Ingemar Kihlström to the studio to talk about Mia's decision to step down as CEO of the company, among other things. We also discuss the drug candidate RCD405, which is currently being prepared for phase I studies.

Watch the interview with Arcede Pharmas vd Mia Lundblad and Chairman of the Board Ingemar Kihlstrom hereinafter.

This material has been prepared for marketing purposes and is not and shall not be considered to constitute a prospectus under applicable laws and regulations. The full terms of the rights issue and further information about the company have been set out in an offering memorandum which was published and published on arcedepharma.com on 21 August 2023.